E-submission
Search
- Page Path
- HOME > Search
Original Article
- Evaluation of the VE1 Antibody in Thyroid Cytology Using Ex Vivo Papillary Thyroid Carcinoma Specimens
- Yon Hee Kim, Hyunee Yim, Yong-Hee Lee, Jae Ho Han, Kyi Beom Lee, Jeonghun Lee, Euy Young Soh, Seon-Yong Jeong, Jang-Hee Kim
- J Pathol Transl Med. 2016;50(1):58-66. Published online December 14, 2015
- DOI: https://doi.org/10.4132/jptm.2015.10.10
- 9,477 View
- 76 Download
- 9 Web of Science
- 10 Crossref
-
Abstract
PDF - Background
Recently, VE1, a monoclonal antibody against the BRAFV600E mutant protein, has been investigated in terms of its detection of the BRAFV600E mutation. Although VE1 immunostaining and molecular methods used to assess papillary thyroid carcinoma in surgical specimens are in good agreement, evaluation of VE1 in thyroid cytology samples is rarely performed, and its diagnostic value in cytology has not been well established. In present study, we explored VE1 immunoexpression in cytology samples from ex vivo papillary thyroid carcinoma specimens in order to minimize limitations of low cellularity and sampling/targeting errors originated from thyroid fineneedle aspiration and compared our results with those obtained using the corresponding papillary thyroid carcinoma tissues. Methods: The VE1 antibody was evaluated in 21 cases of thyroid cytology obtained directly from ex vivo thyroid specimens. VE1 immunostaining was performed using liquid-based cytology, and the results were compared with those obtained using the corresponding tissues. Results: Of 21 cases, 19 classic papillary thyroid carcinomas had BRAFV600E mutations, whereas two follicular variants expressed wild-type BRAF. VE1 immunoexpression varied according to specimen type. In detection of the BRAFV600E mutation, VE1 immunostaining of the surgical specimen exhibited 100% sensitivity and 100% specificity, whereas VE1 immunostaining of the cytology specimen exhibited only 94.7% sensitivity and 0% specificity. Conclusions: Our data suggest that VE1 immunostaining of a cytology specimen is less specific than that of a surgical specimen for detection of the BRAFV600E mutation, and that VE1 immunostaining of a cytology specimen should be further evaluated and optimized for clinical use. -
Citations
Citations to this article as recorded by
- Principles of Analytic Validation of Immunohistochemical Assays: Guideline Update
Jeffrey D. Goldsmith, Megan L. Troxell, Sinchita Roy-Chowdhuri, Carol F. Colasacco, Mary Elizabeth Edgerton, Patrick L. Fitzgibbons, Regan Fulton, Thomas Haas, Patricia L. Kandalaft, Tanja Kalicanin, Christina Lacchetti, Patti Loykasek, Nicole E. Thomas,
Archives of Pathology & Laboratory Medicine.2024; 148(6): e111. CrossRef - Inter- and Intra-observer Reproducibility of Thyroid Fine Needle Aspiration Cytology: An investigation of Bethesda 2023 Using Immunohistochemical BRAFV600E Antibody
Erdogan Bahattin, Dündar Emine, Çetin Kısmet Çivi, Yılmaz Fatih
Journal of Cytology.2024; 41(4): 221. CrossRef - VE1 immunohistochemistry is an adjunct tool for detection of BRAFV600E mutation: Validation in thyroid cancer patients
Faiza A. Rashid, Sobia Tabassum, Mosin S. Khan, Hifzur R. Ansari, Muhammad Asif, Ahmareen K. Sheikh, Syed Sameer Aga
Journal of Clinical Laboratory Analysis.2021;[Epub] CrossRef - Effective utilization of liquid-based cytology for thyroid lesions
Yukie YAMAYA
The Journal of the Japanese Society of Clinical Cytology.2021; 60(3): 164. CrossRef - Diagnostic Efficacy of BRAFV600E Immunocytochemistry in Thyroid Aspirates in Bethesda Category IV and Papillary Thyroid Carcinoma
Nidhi Anand, Tushar Agrawal, Anurag Gupta, Saumya Shukla, Roma Pradhan, Nuzhat Husain
Journal of Cytology.2021; 38(3): 113. CrossRef - The immunocytochemical expression of VE‐1 (BRAF V600E‐related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid‐based cytology
Patrizia Straccia, Chiara Brunelli, Esther D. Rossi, Paola Lanza, Maurizio Martini, Teresa Musarra, Celestino Pio Lombardi, Alfredo Pontecorvi, Guido Fadda
Cytopathology.2019; 30(5): 460. CrossRef - Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma
Amber L. Smith, Michelle D. Williams, John Stewart, Wei‐Lien Wang, Savitri Krishnamurthy, Maria E. Cabanillas, Sinchita Roy‐Chowdhuri
Cancer Cytopathology.2018; 126(6): 406. CrossRef - Refinement of the criteria for ultrastructural peritubular capillary basement membrane multilayering in the diagnosis of chronic active/acute antibody-mediated rejection
Heounjeong Go, Sung Shin, Young Hoon Kim, Duck Jong Han, Yong Mee Cho
Transplant International.2017; 30(4): 398. CrossRef - Thyroid Fine-Needle Aspiration Cytology Practice in Korea
Yoon Jin Cha, Ju Yeon Pyo, SoonWon Hong, Jae Yeon Seok, Kyung-Ju Kim, Jee-Young Han, Jeong Mo Bae, Hyeong Ju Kwon, Yeejeong Kim, Kyueng-Whan Min, Soonae Oak, Sunhee Chang
Journal of Pathology and Translational Medicine.2017; 51(6): 521. CrossRef - Use of monoclonal antibodies to detect specific mutations in formalin-fixed, paraffin-embedded tissue sections
Zhenying Guo, Ricardo V. Lloyd
Human Pathology.2016; 53: 168. CrossRef
- Principles of Analytic Validation of Immunohistochemical Assays: Guideline Update
First
Prev
